Abstract
Intramyocardial injection of heart explant-derived cells (EDCs) improves cardiac function in preclinical models of ischemic cardiomyopathy. This therapeutic benefit is partially attributable to the anti-inflammatory cargo (micro RNAs and proteins) enriched within the extracellular vesicles (EVs) released by EDCs. Recent work has shown that activation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome in both immune and non-immune cells plays a critical role in promoting cardiac inflammation and adverse remodeling.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
